Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female, 18 years or older~* blood culture positive for S. aureus~* at least one sign or symptom attributable to S. aureus bacteremia~* known or suspected complicated S. aureus BSI and/or endocarditis by Modified Duke Criteria~* patient is not pregnant or breastfeeding and is not of reproductive potential or agrees to use contraception if of reproductive potential.~Exclusion Criteria:~* patient previously received CF-301.~* treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 72 hours within 7 days before randomization.~* presence of any removable infection source that will not be removed or debrided within 72 hours after randomization.~* brain abscess or meningitis.~* community acquired pneumonia or known polymicrobial bacteremia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CF-301 (Type: EXPERIMENTAL): Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).